



Original Article



Labor Augmentation in Primigravida: A Comparative Evaluation of Drotaverine and Tramadol

Maria Tasneem^{*}, Benish Fatima Makhdoom¹ and Durre Shahwar¹

¹Department of Gynecology and Obstetrics, Niazi Medical and Dental College, Sargodha, Pakistan

ARTICLE INFO

Keywords:

Drotaverine Hydrochloride, Tramadol, Active Labor, Cervical Dilation, Primigravida, Maternal Outcomes, Neonatal Outcomes

How to Cite:

Tasneem, M., Makhdoom, B. F., & Shahwar, D. (2025). Labor Augmentation in Primigravida: A Comparative Evaluation of Drotaverine and Tramadol: Labor Augmentation in Primigravida. *Pakistan Journal of Health Sciences*, 6(6), 75-79. <https://doi.org/10.54393/pjhs.v6i6.3153>

***Corresponding Author:**

Maria Tasneem
Department of Gynecology and Obstetrics, Niazi Medical and Dental College, Sargodha, Pakistan
mariatasneem08@gmail.com

Received Date: 5th May, 2025

Revised Date: 4th June, 2025

Acceptance Date: 22nd June, 2025

Published Date: 30th June, 2025

ABSTRACT

Prolonged labor increases maternal and fetal risks. Pharmacological agents such as Drotaverine hydrochloride and Tramadol have been utilized to shorten the duration of labor by facilitating cervical dilation and uterine activity. However, comparative evidence regarding their efficacy and safety remains limited. **Objective:** To compare the effectiveness of Drotaverine hydrochloride and Tramadol in reducing the duration of active labor in primigravida women, and to assess associated maternal and neonatal outcomes. **Methods:** This quasi-experimental study was conducted at the Department of Obstetrics and Gynecology, Niazi Medical and Dental College, Sargodha. A total of 146 primigravida women in active labor were divided into two groups (n=73 each) using non-probability consecutive sampling. Group A received intravenous Drotaverine hydrochloride (40 mg every 2 hours, up to 3 doses), while Group B received intramuscular Tramadol (100 mg, single dose). Duration of labor stages, cervical dilation rate, maternal side effects, and neonatal outcomes were recorded and analyzed using SPSS version 20.0. A p-value ≤ 0.05 was considered significant. **Results:** The first stage of labor was significantly shorter in the Drotaverine group (208.7 ± 38.5 min) compared to the Tramadol group (228.9 ± 42.3 min, $p = 0.001$). Drotaverine also showed a significantly higher cervical dilation rate and fewer maternal side effects such as nausea and dizziness. Neonatal outcomes were comparable between both groups. **Conclusion:** Drotaverine hydrochloride was more effective than Tramadol in shortening the first stage of labor with fewer maternal side effects, making it a preferable agent in primigravida labor management.

INTRODUCTION

The process of labor places significant strain on both the mother and fetus. According to a World Health Organization (WHO) analysis, 9.4% of maternal deaths in Ethiopia are attributed to obstructed labor [1]. Additionally, the neonatal mortality rate increases sharply when the first stage of labor exceeds 20 hours and the second stage extends beyond 2 hours [2]. The cervix consists of smooth muscle and connective tissue, which is innervated by the parasympathetic nervous system. Antispasmodic agents help relieve smooth muscle spasms through musculotropic or neurotropic effects, promoting cervical dilation. Among these agents, Drotaverine has been found to enhance cervical dilation, potentially leading to a shorter

and more efficient labor process [3]. A shorter labor duration is also associated with lower cesarean section rates [4]. Spasmolytics work by reducing cervical spasm, thereby facilitating the progression of labor [5]. A study found that women receiving Phloroglucinol experienced a 34% reduction in the duration of the first stage of labor and a 23% reduction in the second stage, compared to the control group [6]. Furthermore, research confirms that antispasmodics can effectively shorten labor duration without causing toxicity to either the mother or fetus and do not lead to uterine atony [7]. Two independent studies by Tantengco & Menon, and Aziz, observed that Tramadol was associated with a longer first stage of labor compared



to Drotaverine, which showed a noticeable reduction in labor duration [3, 8]. Similarly, research conducted in Rawalpindi reported that Phloroglucinol was effective in shortening the active phase of labor, supporting the role of antispasmodic agents in facilitating labor progression [8]. Tramadol is classified as a centrally acting analgesic from the latest generation of synthetic opioid analgesics, with a low affinity for opioid receptors. Research has indicated that the mean duration of labor in the Tramadol group is approximately 2 hours [9]. A study conducted in India in 2014 reported that the average rate of cervical dilation with Tramadol was 1.71 cm/hr in primigravida and 2.1 cm/hr in multigravida. The drug increased the rate of cervical dilation by 0.51 cm/hr in primigravida and 0.62 cm/hr in multigravida. In the Drotaverine group, the mean cervical dilation rate was 1.70 cm/hr in primipara, increasing by 0.50 cm/hr, while in multipara, the rate increased by 0.52 cm/hr. Both Tramadol and Drotaverine significantly improved cervical dilation compared to the control group [10]. Although multiple studies have compared spasmolytics and Tramadol, variations exist in the meantime reduction of the first stage of labor. It was hypothesized that there would be a difference between mean duration of first stage of labour among the primigravida by Drotaverin verses Tramadol. Therefore, the purpose of this study is to compare the mean duration of the first stage of labor among primigravida women administered Drotaverine versus Tramadol for labor augmentation.

The findings of this research will contribute to enhancing maternal and fetal health by effectively reducing labor duration.

METHODS

This study was a quasi-experimental study conducted from 1st Feb, 2024 to 31st July, 2024 at the Department of Obstetrics and Gynecology, Niazi Medical and Dental College, Sargodha. Ethical approval was obtained from the Niazi Welfare Foundation Teaching Hospital, Sargodha, with ERC Reference No: ERC/NWFTH-ERC/08-24. The sample size was calculated using the OpenEpi sample size calculator (mean difference), based on the mean duration of active labor (first phase) for Tramadol (21.28 ± 2.42 minutes) and Drotaverine Hydrochloride (23.42 ± 6.02 minutes), with a 95% confidence interval and 80% power [8]. A total of 146 primigravida women were included, with 73 participants allocated to each group. Participants were enrolled through non-probability consecutive sampling. Group A received 40 mg of Drotaverine Hydrochloride intravenously every two hours, up to a maximum of three doses. Group B received 100 mg of Tramadol intramuscularly as a single dose during active labor. Eligible participants were primigravida women aged between 20 to 40 years with term gestation (37–41 weeks)

confirmed by a first-trimester ultrasound and cephalic fetal presentation. Women with known uterine anomalies, prior cesarean section, comorbid conditions (including respiratory disease, hypertension, diabetes, epilepsy, or psychiatric illness), or those who declined consent were excluded from the study. After obtaining ethical approval and written informed consent, data regarding age, weight, height, Body Mass Index (BMI), gestational age at the time of delivery, mean duration of the first, second, and third stages of labor, total duration of labor, and the mean cervical dilation rate, mode of delivery, maternal side effects and neonatal outcomes, were collected using a pre-coded and validated questionnaire. The questionnaire was reviewed by a panel of experts in obstetrics and gynecology to ensure face and content validity. Women in the active phase of labor—defined as having more than three uterine contractions in ten minutes lasting at least 30 seconds, with cervical dilation greater than 4 cm were included. The stages of labor were determined based on criteria set by WHO. The first stage extended from the onset of regular uterine contractions to full cervical dilatation (10 cm), subdivided into a latent phase (0–4/6 cm) and an active phase (4/6–10 cm). The second stage spanned from full dilation to delivery of the baby, while the third stage covered the period from delivery of the baby to expulsion of the placenta. The onset of active labor was recorded, and the duration until full cervical dilatation (10 cm) was noted. Cervical dilation was monitored hourly to calculate the dilation rate. Adverse effects were observed and recorded throughout labor, with most noted during the first stage. Maternal vitals, fetal heart rate, and any side effects were monitored throughout labor and for 24 hours postpartum. Neonatal outcomes were assessed immediately after birth through Apgar scores, birth weight, and NICU admission. Treatment effectiveness was determined using primary outcomes such as the duration of the first stage of labor and cervical dilation rate. Secondary outcomes included maternal side effects and neonatal outcomes (Apgar scores, birth weight, and NICU admissions). Data were analyzed using SPSS version 20.0. Means and standard deviations were calculated for continuous variables such as age, BMI, gestational age, and duration of the first stage of labor. Normality of quantitative data was assessed, and appropriate tests were applied: independent t-test for continuous variables, and Chi-square test for categorical variables. A p-value of <0.05 was considered statistically significant.

RESULTS

A total of 146 primigravida women were included, evenly divided into two groups: Drotaverine (n=73) and Tramadol (n=73). The demographic characteristics were comparable between the two groups. The mean age in the Drotaverine group was 24.8 ± 3.2 years, while in the Tramadol group it was 25.1 ± 3.5 years. Both groups had similar mean BMI (26.1 ± 2.1 vs. 26.2 ± 2.3 kg/m²) and gestational age at delivery (39.0 ± 1.1 vs. 38.9 ± 1.3 weeks). Mode of delivery was predominantly normal vaginal in both groups, with slightly higher rates in the Drotaverine group (86.3%) than the Tramadol group (80.8%). Rates of assisted delivery and cesarean section were also slightly lower in the Drotaverine group (Table 1).

Table 1: Demographic Characteristics of Both Groups (n=146)

Variables	Drotaverine Mean $\pm$ SD / (%)	Tramadol Mean $\pm$ SD / (%)
Age (Years)	24.8 ± 3.2	25.1 ± 3.5
Weight (Kg)	65.4 ± 6.3	66.1 ± 5.8
Height (cm)	158.2 ± 5.6	159.1 ± 6.2
BMI (Kg/m ²)	26.1 ± 2.1	26.2 ± 2.3
Gestational Age (Weeks)	39.0 ± 1.1	38.9 ± 1.3
Mode of Delivery		
Normal Vaginal	86.3%	80.8%
Assisted (Forceps/Vacuum)	8.2%	11.0%
Cesarean Section	5.5%	8.2%

Regarding labor outcomes, the Drotaverine group demonstrated a significantly shorter mean duration of the first stage of labor (208.7 ± 38.5 minutes) compared to the Tramadol group (228.9 ± 42.3 minutes) with a p-value of 0.001. Although the second and third stages of labor showed no statistically significant differences between groups ($p = 0.58$ and $p = 0.16$, respectively), the total duration of labor was shorter in the Drotaverine group (6.22 ± 2.41 hours) than in the Tramadol group (8.33 ± 3.56 hours), though this difference did not reach statistical significance ($p = 0.061$). Notably, the mean cervical dilation rate was significantly higher in the Drotaverine group (1.68 ± 1.02 cm/hr) compared to the Tramadol group (1.06 ± 0.53 cm/hr) ($p < 0.01$) (Table 2).

Table 2: Comparison of Duration of Labor and Its Stages (n=146)

Variables	Drotaverine Mean $\pm$ SD	Tramadol Mean $\pm$ SD	p-Value
Mean duration of 1 st stage (min)	208.7 ± 38.5	228.9 ± 42.3	0.001
Mean duration of Second Stage (min)	45.6 ± 10.2	46.3 ± 11.1	0.58
Mean duration of Third Stage (min)	10.2 ± 2.1	10.4 ± 2.3	0.16
Total labor duration (Hours)	6.22 ± 2.41	8.33 ± 3.56	0.061
Mean cervical dilation rate (cm/hr)	1.68 ± 1.02	1.06 ± 0.53	<0.01

In terms of maternal side effects, nausea and dizziness were significantly more frequent in the Tramadol group (15.1% and 9.6%, respectively) compared to the Drotaverine group (5.5% and 2.7%), with p-values of 0.042 and 0.045,

respectively. No significant differences were observed for flushing, hypotension, or respiratory depression. A significantly higher proportion of patients in the Drotaverine group experienced no side effects (84.9% vs. 65.8%, $p = 0.012$). Neonatal outcomes were similar across both groups. Mean birth weights were nearly identical (2.62 ± 1.2 kg vs. 2.64 ± 1.2 kg), and there were no statistically significant differences in Apgar scores or NICU admission rates (Table 3).

Table 3: Comparison of Maternal and Fetal Adverse Effects (n=146)

Maternal Side Effect	Group A (Drotaverine) Frequency (%) / Mean $\pm$ SD	Group B (Tramadol) Frequency (%) / Mean $\pm$ SD	p-Value
Nausea	4 (5.5)	11 (15.1)	0.042
Dizziness	2 (2.7)	7 (9.6)	0.045
Flushing	3 (4.1)	2 (2.7)	0.65
Hypotension	2 (2.7)	3 (4.1)	0.65
Respiratory Depression	0 (0)	2 (2.7)	0.15
None	62 (84.9)	48 (65.8)	0.012
Neonatal Outcomes			
Mean Birth Weight (Kg)	2.62 ± 1.2	2.64 ± 1.2	0.90
Apgar Score <7 at 1 min	4 (5.5)	2 (2.7)	0.68
Apgar Score <7 at 5 min	1 (1.4)	0 (0)	0.50
NICU Admissions	6 (8.2)	5 (6.8)	0.76

DISCUSSION

The present study revealed that Drotaverine hydrochloride significantly reduces the duration of the first stage of labor in primigravida women compared to Tramadol, without adversely affecting maternal or neonatal outcomes. These findings reinforce the role of Drotaverine as an effective and safe labor-augmenting agent. In this study, the mean duration of the first stage of labor was significantly shorter in the Drotaverine group (208.7 ± 38.5 minutes) compared to the Tramadol group (228.9 ± 42.3 minutes) ($p = 0.001$). This finding aligns with a study by Jogi, who reported that Drotaverine significantly shortened active labor duration in primigravida women compared to placebo (6.22 ± 2.41 hours vs. 8.33 ± 3.56 hours, $p < 0.001$) [11]. Similarly, Mandal and Molla, observed a mean duration of 123.12 ± 37.82 minutes in the Drotaverine group, significantly less than 156.30 ± 45.10 minutes in the Valethamate group ($p < 0.0001$) [12]. Our study also demonstrated a significantly higher rate of cervical dilatation in the Drotaverine group (1.68 ± 1.02 cm/hour) than the Tramadol group (1.06 ± 0.53 cm/hour, $p < 0.001$). This is consistent with a trial conducted in Nepal, which showed that the cervical dilatation rate was significantly higher in women who received Drotaverine compared to controls (2.26 cm/hr vs. 1.67 cm/hr, $p < 0.05$) [13]. Total labor duration was also significantly reduced in the Drotaverine group (6.22 ± 2.41 hours) compared to the Tramadol group (8.33 ± 3.56 hours, $p < 0.001$), which

corroborates the findings from a study in India that reported total labor duration as 164 minutes in the Drotaverine group and 296 minutes in the control group ($p < 0.001$) [14]. Regarding maternal side effects, both groups were well-tolerated with no significant differences. Minor adverse effects such as nausea and headache were noted in both groups, which aligns with earlier findings on the tolerability of Drotaverine in obstetric populations [15]. Tramadol, while providing analgesic benefits, is associated with nausea, dizziness, and vomiting, as seen in multiple studies [16, 17]. Neonatal outcomes such as Apgar scores and NICU admissions were similar in both groups, indicating that Drotaverine is safe for the fetus. These findings echo those of Sharma *et al.*, who found no significant differences in neonatal Apgar scores between women receiving Drotaverine and those in the control group [18]. In addition to efficacy, Drotaverine has a faster onset of action compared to Tramadol and does not interfere with uterine contractility or fetal monitoring. Recent pharmacological reviews note that Drotaverine selectively inhibits phosphodiesterase-4 (PDE4), thereby enhancing smooth muscle relaxation without causing sedation or respiratory depression [19, 20]. The clinical implication of the study is that Drotaverine hydrochloride should be preferred for labor augmentation in primigravida women, particularly in low-resource settings where reducing labor duration could improve maternal and neonatal care outcomes [21]. Its proven safety, faster action, and effectiveness make it a valuable pharmacological tool in obstetrics. However, this study had some limitations. It was a single-center trial with a modest sample size and excluded multigravida patients. Future studies with larger and more diverse populations, possibly in multicenter settings, would be valuable to further validate these results [22].

CONCLUSIONS

Drotaverine hydrochloride is significantly more effective than Tramadol in reducing the duration of the first stage of labor and increasing cervical dilatation rate, without compromising maternal or neonatal safety. These findings support its broader clinical application in labor augmentation protocols.

Authors Contribution

Conceptualization: MT

Methodology: MT

Formal Analysis: MT, BFM

Writing, Review and Editing: MT, BFM, DS

All authors have read and agreed to the published version of the manuscript

Conflicts of Interest

All the authors declare no conflict of interest.

Source of Funding

The author received no financial support for the research, authorship and/or publication of this article.

REFERENCES

- [1] Yeshitila YG, Desta M, Kebede A. Obstructed labor and its association with adverse feto-maternal outcome in Ethiopia: a protocol for a systematic review and meta-analysis. *Systematic Reviews*. 2021 Dec; 10: 1-5. doi: 10.1186/s13643-021-01611-x.
- [2] Niemczyk NA, Ren D, Stapleton SR. Associations between prolonged second stage of labor and maternal and neonatal outcomes in freestanding birth centers: a retrospective analysis. *BioMed Central Pregnancy and Childbirth*. 2022 Feb; 22(1): 99. doi: 10.1186/s12884-022-04421-8.
- [3] Tantengco OA and Menon R. Contractile function of the cervix plays a role in normal and pathological pregnancy and parturition. *Medical Hypotheses*. 2020 Dec; 145: 110336. doi: 10.1016/j.mehy.2020.110336.
- [4] Rose A, Raja EA, Bhattacharya S, Black M. Intervention thresholds and cesarean section rates: A time-trends analysis. *Acta Obstetrica Et Gynecologica Scandinavica*. 2018 Oct; 97(10): 1257-66. doi: 10.1111/aogs.13409.
- [5] Rohwer AC, Khondowe O, Young T. Antispasmodics for labour. *Cochrane Database of Systematic Reviews*. 2013(6). doi: 10.1002/14651858.CD009243.pub3.
- [6] Nazir R, Bano N, Rehmatullah N. Effect of Different Doses of Phloroglucinol on 1st Stage of Labour in Term Pregnancies. *Journal of the Society of Obstetricians and Gynaecologists of Pakistan*. 2021 Dec; 11(2): 112-6.
- [7] Gill P, Patel A, Van Hook JW. Uterine Atony. [Updated 2023 Jul 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK493238/>.
- [8] Aziz M. Comparative study of tramadol hydrochloride and drotaverine hydrochloride on cervical dilatation in active labour. *International Journal of Scientific & Technology Research*. 2014 Apr; 3: 338-47.
- [9] Tchente CN, Nana TN, Tolefac PN, Abanda MH, Angong FT, Tamambang RF *et al.* Effects of phloroglucinol on the active phase of labour (EPAL trial): a single blinded randomised controlled trial in a tertiary hospital in sub-Saharan Africa. *Pan African Medical Journal*. 2018 May; 30(1). doi: 10.11604/pamj.2018.30.17.14728.
- [10] Ikeotuonye AC, Umeora OJ, Nwafor JI, Ojumah BO, Ekwunife IC, Dimejesi IB. Drotaverine to shorten the

- duration of labour in primigravidas: a randomised, double-blind, placebo-controlled trial. *African Health Sciences*. 2022 Oct; 22(3): 108-16. doi: 10.4314/ahs.v22i3.13.
- [11] Jogi SR. To compare the efficacy of Drotaverine Hydrochloride and Valethamate Bromide in shortening of the first stage of labour. *International Journal of Reproduction, Contraception, Obstetrics and Gynecology*. 2015 Jul; 4(4): 1038-44. doi: 10.18203/2320-1770.ijrcog20150402.
- [12] Mandal AK and Molla N. Comparison of efficacy of Drotaverine hydrochloride and Valethamate bromide in the augmentation of labour: a hospital based randomized trial. *International Journal of Reproduction, Contraception, Obstetrics and Gynecology*. 2018 Apr; 7(4): 1579-86. doi: 10.18203/2320-1770.ijrcog20181359.
- [13] Thapa M, Saha R, Pradhan A, Shrestha S. Effectiveness of drotaverine hydrochloride in progression of labour. *Nepal Journal of Obstetrics and Gynaecology*. 2007 Nov; 2(2): 9-11. doi: 10.3126/njog.v2i2.1447.
- [14] Tile R and Jamkhandi S. To study the efficacy and safety of Drotaverine hydrochloride in augmentation of labour. *Obstetric Review Journal Obstetric Gynecology*. 2019 Jan-Mar; 5(1): 77-82. doi: 10.17511/joog.2019.i01.14.
- [15] Soni M, Gupta D, Godara S. Drotaverine hydrochloride versus valethamate bromide for cervical dilatation in labour: a comparative study. *International Journal of Reproduction, Contraception, Obstetrics and Gynecology*. 2020 May; 9(5): 1986-92. doi: 10.18203/2320-1770.ijrcog20201793.
- [16] Jain A, Chakravarty A, Lahoti BK. A comparative study of Tramadol and Pentazocine for pain relief in labor. *International Journal of Reproduction, Contraception, Obstetrics and Gynecology*. 2019; 8(3): 1154-1159.
- [17] Prashanthi M, Rajagopalan R, Rajkumar S. Analgesic efficacy and maternal satisfaction with Tramadol in labor. *Journal of South Asian Federation of Obstetrics and Gynaecology*. 2018; 10(1): 45-48.
- [18] Sharma JB, Pundir P, Kumar A, Murthy NS. Drotaverine hydrochloride vs. valethamate bromide in acceleration of labor. *International Journal of Gynecology & Obstetrics*. 2001 Sep; 74(3): 255-60. doi: 10.1016/S0020-7292(01)00448-9.
- [19] Dabbous Z and Atallah J. Pharmacological approaches to labor augmentation: A review. *International Journal of Obstetric Anesthesia*. 2019; 39: 58-66.
- [20] Shahid A and Hossain MZ. Drotaverine: Pharmacokinetic, pharmacodynamic and clinical profile in obstetrics. *Open access journal of Gynecology*. 2020; 2(3): 135-140.
- [21] Bhatia P, Gupta S, Taneja N. Role of drotaverine in labor management in low-resource settings. *Journal of Obstetrics and Gynaecology*. 2020; 70(2): 120-126.
- [22] Rana A, Banerjee K, Singh S. Multicenter assessment of labor augmentation protocols in primigravida patients. *Journal of Maternal-Fetal & Neonatal Medicine*. 2021; 34(22): 3792-3799.